6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting. Issue 3 (March 2022)

Record Type:: Journal Article
Title:: 6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting. Issue 3 (March 2022)
Main Title:: 6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting
Authors:: Becerra-Chauca, Naysha
Nieto-Gutierrez, Wendy
Taype-Rondan, Alvaro
Abstract:
Is Part Of:: Lancet oncology. Volume 23:Issue 3(2022)
Journal:: Lancet oncology
Issue:: Volume 23:Issue 3(2022)
Issue Display:: Volume 23, Issue 3 (2022)
Year:: 2022
Volume:: 23
Issue:: 3
Issue Sort Value:: 2022-0023-0003-0000
Page Start:: e100
Page End:
Publication Date:: 2022-03
Subjects:: Oncology -- Periodicals
Neoplasms -- Periodicals
Cancérologie -- Périodiques
Oncologie
Oncology
Periodicals
Electronic journals
616.994005
Journal URLs:: http://www.sciencedirect.com/science/journal/14702045 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S1470-2045(22)00060-2 ↗
Languages:: English
ISSNs:: 1470-2045
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5146.090000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 21146.xml